Here are the S-3 shelf registrations from Alto Neuroscience Inc. (ANRO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow ANRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANRO filings page.
Alto Neuroscience filed a shelf registration to permit resale of up to 6,000,000 shares of common stock by recent private placement investors. The shares consist of 2,900,000 issued shares and 3,100,000 shares issuable upon exercise of pre-funded warrants. Alto received approximately $120.0 million gross proceeds from the Private Placement that closed on March 17, 2026. The company will not receive proceeds from resale by the selling stockholders, except for the nominal $0.0001 per-share exercise price if any Pre-Funded Warrants are exercised for cash. The registration covers resale mechanics, selling-stockholder tables (examples provided), and related indemnities and distribution methods. Alto common stock trades on the NYSE under ANRO (closing price shown April 9, 2026: $22.40).
Alto Neuroscience, Inc. has filed a resale registration statement covering up to 8,454,514 shares of common stock for selling stockholders. The shares consist of 3,832,263 outstanding shares and 4,622,251 shares issuable upon exercise of pre-funded warrants from an October 2025 private placement. Alto will not receive proceeds from any stockholder sales, but will receive the $0.0001 per share exercise price if the pre-funded warrants are exercised for cash.
Alto is a clinical-stage biopharmaceutical company using its Precision Psychiatry Platform to develop biomarker-driven treatments for major depressive disorder, bipolar depression, treatment-resistant depression and schizophrenia, with seven clinical-stage assets. The October 2025 private placement raised approximately $50.0 million at $5.914 per share, and Alto reported 31,034,019 shares outstanding as of October 21, 2025 following that financing.